Stock Locations

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

397864-44-7Fluticasone Furoate Working Standard (Secondary Reference Standard)

● Under Development

Catalogue No.:	VE0010059
CAS No.:	397864-44-7
Mol. Formula:	C27H29F3O6S
Mol. Weight:	538.58 g/mol

How can we help?

Add to RFQ list

Additional information on CAS 397864-44-7

Parent drug

Fluticasone Furoate

IUPAC Name

(6α,11β,16α,17α)-6,9-Difluoro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioic Acid S-(Fluoromethyl) Ester

Synonyms

N/A

Pharmacopeial Synonyms

N/A

Smiles

C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(C5=CC=CO5)=O)C(SCF)=O)=O

InChI

InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1

Description

Fluticasone Furoate Working Standard (Secondary Reference Standard), CAS 397864-44-7, is a characterized secondary reference material provided for analytical laboratories and research organizations and is traceable to an applicable pharmacopeial reference standard such as USP, BP, JP, or Ph. Eur., as applicable. It is intended for research and analytical use. Supplied with a comprehensive certificate of analysis documenting identity by relevant analytical techniques such as mass, 1H NMR, and FT-IR, together with assay by HPLC and other applicable quality attributes such as loss on drying and residual solvents, this working standard is suitable for analytical laboratory use where consistent and well-documented secondary reference material is required.

References

Giavina-Bianchi, P. (2008). Fluticasone furoate nasal spray in the treatment of allergic rhinitis. Therapeutics and Clinical Risk Management, Volume 4, 465â€“472. https://doi.org/10.2147/tcrm.s1984